Jupiter Neurosciences (NASDAQ:JUNS) Stock Price Down 4.6% – Here’s Why

Jupiter Neurosciences, Inc. (NASDAQ:JUNS) shares dropped 4.6% on Monday . The stock traded as low as $0.2250 and last traded at $0.2310. Approximately 1,872,972 shares changed hands during mid-day trading, a decline of 90% from the average daily volume of 18,390,686 shares. The stock had previously closed at $0.2421.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Jupiter Neurosciences in a research report on Friday, March 27th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the company has an average rating of “Sell”.

Jupiter Neurosciences Trading Down 2.9%

The business has a fifty day moving average price of $0.33 and a 200 day moving average price of $0.64.

Jupiter Neurosciences (NASDAQ:JUNS) last issued its quarterly earnings results on Thursday, May 14th. The company reported ($0.06) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.01). The firm had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.23 million.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of JUNS. Allen Capital Group LLC acquired a new position in shares of Jupiter Neurosciences during the fourth quarter worth approximately $31,000. Yorkville Advisors Global LP acquired a new position in shares of Jupiter Neurosciences during the fourth quarter worth approximately $135,000. Geode Capital Management LLC lifted its holdings in shares of Jupiter Neurosciences by 27.8% during the fourth quarter. Geode Capital Management LLC now owns 132,641 shares of the company’s stock worth $135,000 after buying an additional 28,826 shares during the last quarter. Finally, Vestor Capital LLC raised its stake in shares of Jupiter Neurosciences by 144,607.2% in the first quarter. Vestor Capital LLC now owns 970,985 shares of the company’s stock valued at $365,000 after purchasing an additional 970,314 shares in the last quarter.

About Jupiter Neurosciences

Jupiter Neurosciences, Inc, a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer's disease.